The role of leptin in the regulation of TSH secretion in the fed state: in vivo and in vitro studies

T M Ortiga-Carvalho, K J Oliveira, B A Soares and C C Pazos-Moura

Laboratório de Endocrinologia Molecular, Instituto de Biologia Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Universidade do Brasil, CCS-Cidade Universitária, Ilha do Fundão, Rio de Janeiro, Brazil

(Requests for offprints should be addressed to C C Pazos-Moura; Email: cpazosm@biof.ufrj.br)

Abstract

Leptin has been shown to stimulate the hypothalamus–pituitary–thyroid axis in fasting rodents; however, its role in thyroid axis regulation under physiological conditions is still under investigation. Here it was investigated in freely fed rats whether leptin modulates thyrotroph function in vivo and whether leptin has direct pituitary effects on TSH release. Since leptin is produced in the pituitary, the possibility was also investigated that leptin may be a local regulator of TSH release. TSH was measured by specific RIA. Freely fed adult rats 2 h after being injected with a single s.c. injection of 8 µg leptin/100 g body weight showed a 2-fold increase in serum TSH (P<0·05). Hemi-pituitary explants incubated with 10^-9 and 10^-7 M leptin for 2 h showed a reduced TSH release of 40 and 50% respectively (P<0·05). Conversely, incubation of hemi-pituitary explants with antiserum against leptin, aiming to block the action of locally produced leptin, resulted in higher TSH release (45%, P<0·05). In conclusion, also in the fed state, leptin has an acute stimulatory effect on TSH release in vivo, acting probably at the hypothalamus. However, the direct pituitary effect of leptin is inhibitory and data also provide evidence that in the rat pituitary leptin may act as an autocrine/paracrine inhibitor of TSH release.


Introduction

Leptin, a satiety factor produced mainly in the adipose tissue, is also involved in the neuroendocrine regulation of pituitary function (Ahima et al. 2000). Most studies concerning leptin action on the thyroid axis focus on the fasting situation and favour the concept that leptin acts primarily on the hypothalamus, stimulating directly or indirectly thyrotrophin-releasing hormone (TRH) production and release (Legradi et al. 1997, Kim et al. 2000, Nillni et al. 2000, Harris et al. 2001). In fasting rats, the administration of leptin partially prevents the fall in serum thyroid hormones and thyrotrophin (TSH) induced by fasting (Ahima et al. 1996, Seoane et al. 2000). Although there are convincing reports implicating leptin depletion in the supression of the pituitary–thyroid axis during starvation, the role of leptin in the maintenance of this axis under physiological conditions is unclear. In humans, leptin or leptin receptor deficiency is very rare and, in a few cases, seem to lead to mild central hypothyroidism in children, but not in adults (Montague et al. 1997, Clement et al. 1998, Ozata et al. 1999). In addition, depression of the hypothalamus–pituitary–thyroid axis has not been clearly demonstrated in leptin- or leptin receptor-deficient rodents. There are some reports suggesting that in the early life of obese mice (ob/ob) was presented a mild hypothyroid phenotype (Mobley & Dubuc 1979); however, in adulthood, serum TSH, thyroxine (T₄) and triiodothyronine (T₃) levels are normal (Dubuc 1991) or even slightly higher (Mobley & Dubuc 1979).

The detection of leptin receptor in the human (Jim et al. 1999, Knerr et al. 2001, Korbonits et al. 2001) and rat (Jim et al. 2000, Sone et al. 2001) pituitary gland raises the possibility that circulating leptin might also act directly to modulate TSH release. It has been shown that leptin regulates secretion of other pituitary hormones from isolated glands or cell cultures (Casanueva & Dieguez 1999). It is not known whether TSH release is modulated by a direct pituitary action.

Moreover, recently, leptin was also found in human (Jim et al. 1999), rat and mouse (Jim et al. 2000, Sone et al. 2001) anterior pituitary gland. The local synthesis of leptin is supported by the presence of leptin mRNA, in rat and mouse pituitaries, and in human pituitary adenomas (Morash et al. 1999, Jim et al. 2000, Knerr et al. 2001, Korbonits et al. 2001). Additionally, in rat and mouse pituitaries, thyrotrophs and other pituitary cells express leptin and leptin receptors (Morash et al. 1999, Jim et al.
2000, Korbonits et al. 2001, Knerr et al. 2001). Altogether, the data raise the hypothesis of a local role of leptin as an autocrine/paracrine regulator of TSH release.

Therefore, here we have addressed the questions of whether leptin is able to modulate thyrotroph function in the fed state, whether leptin acts directly at the pituitary and, also, we have investigated the hypothesis that pituitary leptin may be an autocrine/paracrine TSH regulator in the rat pituitary.

Materials and Methods

Animals

Adult male Wistar rats, weighing 250–300 g, were kept under controlled lighting (12 h light:12 h darkness cycle, lights on at 0600 h) and controlled temperature (23 ± 1 °C). All experimental protocols were approved by our institutional animal care committee (CAUAP).

In vivo experiments

The rats were divided into three groups that received a single s.c. injection of 8 or 16 µg/100 g body weight (BW) mouse recombinant leptin (NPHP, NIH, Torrance, CA, USA) or 0·2 ml saline vehicle (control group). The rats were killed by decapitation, 30 min or 120 min after the injection. Serum was obtained from the trunk blood to measure TSH.

In vitro experiments

Animals were killed by decapitation, and their anterior pituitaries were quickly dissected out. Each hemi-pituitary was immediately transferred to one flask containing 1 ml Krebs–Ringer bicarbonate medium (pH 7·4) at 37 °C in an atmosphere of 95% O 2/5% CO 2 in a Dubnoff metabolic shaker. After a 30 min preincubation period, medium was changed to 1 ml medium alone (control) or medium containing mouse recombinant leptin to a final concentration of 10⁻¹¹, 10⁻⁹ or 10⁻⁷ M. At the end of a 2 h incubation an aliquot was removed for TSH measurement.

In another experiment, using the same in vitro system, hemi-pituitaries were incubated in the presence of antiserum against leptin (rabbit anti-mouse leptin; NHPP, NIH) at 1:2000 or 1:500 dilutions. Control hemi-pituitaries were incubated with normal rabbit serum (NRS) at 1:500 dilutions. After 1 h, an aliquot of medium was removed to measure TSH and the incubation was allowed to continue for another 1 h. After incubation, another aliquot was obtained for TSH quantification.

Quantification of TSH

TSH concentration in the serum and in the incubation medium was measured by specific RIA, employing reagents supplied by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) (Torrance, CA, USA), as previously described (Chard 1987, Ortiga-Carvalho et al. 1996), and was expressed in terms of the reference preparation (RP3). Within-assay variation was 7·9%, and the coefficient of variation between assays was 6·7%. Minimum assay detection was 0·52 ng/ml.

Statistical analysis

Data are reported as means ± s.e.m. One-way ANOVA followed by a Student–Newman–Keuls multiple comparisons test was employed for assessment of significance of all data except for serum TSH, which was analysed by ANOVA only after logarithmic transformation (Zar 1996). Differences were considered to be significant at P<0·05.

Results

In vivo experiments

The administration of 8 µg/100 g BW of mouse recombinant leptin to rats induced, after 2 h, a 2-fold increase in serum TSH when compared with control group values (P<0·05, Fig. 1). No significant effect was observed earlier, at 30 min. The higher dose of leptin (16 µg/100 g BW) was not able to significantly change serum TSH.

In vitro experiments

Leptin-incubated hemi-pituitary glands showed a dose-dependent decrease in TSH release, statistically significant at 10⁻³ M and 10⁻⁷ M (P<0·05), with a reduction of 40 and 50% respectively (Fig. 2). The presence of antiserum against leptin at 1:500 dilution for 2 h in incubation media of hemi-pituitaries
resulted in an approximately 40% increase in TSH release ($P<0.05$) as compared with NRS-incubated hemi-pituitaries. Data represent means ± SEM. *$P<0.05$ vs control.

Figure 3 TSH release from isolated rat hemi-pituitary glands after 1 or 2 h incubation in the presence of antiserum against mouse leptin at 1:200 and 1:500 dilution or NRS at 1:500 dilution. $n=12–14$ hemi-pituitaries. Data represent means ± SEM. *$P<0.05$ vs NRS at 2 h.

Discussion

Here we first demonstrated that systemically administered leptin, in an appropriately low dose, has an acute stimulatory effect on TSH secretion in fed rats, as had been observed in fasting rodents by others (Ahima et al. 1996, Seoane et al. 2000). This effect is independent of leptin-induced changes in food intake, since observations were made very shortly after leptin administration (2 h). Therefore, leptin has direct excitatory effects on the hypothalamic–pituitary–thyroid axis in the fed state. Although it is a moderate effect, the results favour a role for leptin in the modulation of the thyroid axis in physiological conditions.

The leptin stimulatory effect on TSH secretion, observed in vivo, is not due to a direct pituitary action, since isolated hemi-pituitaries respond to leptin by decreasing TSH release. Although it is a moderate effect, it is clearly demonstrated at concentrations in a physiological range. Moreover, the increment in TSH release from isolated hemi-pituitaries by immunoneutralization of endogenous pituitary-produced leptin is highly suggestive that leptin acts as an autocrine/paracrine inhibitor of TSH secretion. This possibility is further reinforced by the previous demonstration of the presence of leptin and leptin receptors in rodent thyrotrophs (Jim et al. 2000, Sone et al. 2001). In vivo and in vitro opposite effects on TSH secretion have been shown for other neuropeptides, such as galanin (Ortlecz et al. 1988) and substance P (Mitsuma & Nogimori 1984, Moura et al. 1999).

Korbonits et al. (2001) had shown that leptin induced an increase in TSH release from a somatotroph adenoma in culture. This opposite response to leptin compared with our study may be related to species differences, to the fact that it is an abnormal human tissue or even to the longer time of incubation with leptin (24 h). Nevertheless, the study of Korbonits et al. (2001) further supports the role of pituitary leptin as a local regulator of TSH release.

Our results also seem to indicate that at least acutely, after a rapid increase in the circulation, the leptin stimulatory hypothalamic action on TRH neurons (Nillni et al. 2000, Harris et al. 2001) overrides the direct pituitary inhibitory effect on TSH release. This would argue in favour of the predominance of the hypothalamic effect over the pituitary one. Although it seems true for an acute administration and also in the fasting situation, it would not explain the absence of abnormalities on hormone secretion in adult obese leptin-deficient humans and mice (ob/ob). In ob/ob mice serum TSH, $T_4$ and $T_3$ are reported to be normal (Mobley & Dubach 1979, Dubach 1991) or even slightly higher (Mobley & Dubach 1979). Although there are differences between rodents and humans that are deficient in leptin or leptin receptor, also in humans only children have been reported to have mild central hypothryroidism and the affected adults seem to have a normal thyroid axis (Montague et al. 1997, Clement
et al. 1998, Ozata et al. 1999). However, more studies are necessary to clarify the question of leptin deficiency and its consequences for the thyroid axis in humans.

In addition, a stimulatory effect on serum TSH could not be demonstrated by chronic treatment of fed rats with leptin (Cusin et al. 2000, Nowak et al. 2002). Leptin-treated animals, however, showed higher serum T3 than a saline-injected pair-fed group in association with an increase in liver 5′-deiodinase activity. It is possible that a stimulatory effect on deiodinase, increasing serum T3 feedback at the hypothalamus and the direct inhibitory effect of leptin on the thyrotroph demonstrated in the present study, are counteracting the stimulatory hypothalamic action of leptin. Therefore, leptin seems to have several targets on the thyroid axis, and the physiological effect of leptin may be the result of its various effects on those targets.

The fact that the highest dose of leptin did not change significantly the thyrotroph parameters studied may be consequent to secondary actions of leptin induced by the high but not the low dose. The same dose relationship was observed by other authors studying the adrenal–pituitary axis (Malendowicz et al. 1998), and therefore it is possible that this may be a more general feature of dose-related effects of leptin.

In conclusion, here we first demonstrated that leptin has an in vivo acute stimulatory effect on TSH release in freely fed rats, as others had demonstrated in fasting rats. However, our data demonstrated that the direct action of leptin at the rat pituitary is to inhibit TSH release and, moreover, the present study also showed evidence of a role for locally produced leptin as an autocrine/paracrine inhibitor of TSH release. Overall, the results lead to the suggestion that the physiological role of leptin on TSH release, at least in rats, may be the result of a stimulatory effect at the hypothalamus and inhibitory at the pituitary.

Acknowledgements

The authors thank Dr A Parlow, National Pituitary Program (NIDDK) for kindly providing us with the recombinant mouse leptin and antisera against leptin. This research was supported by CNPq, CEPG/UFRJ, and FAPEFJ.

References


Möbley PW & Dubuc PU 1979 Thyroid hormone levels in the developing obese-hyperglycemic syndrome. Hormone Metabolism Research 11 37–39.


Received 29 January 2002
Accepted 4 April 2002